Summary
Zoetis Inc. reported a net loss of $37 million for the second quarter of 2015, a significant shift from the $136 million net income in the same period last year. This was largely driven by substantial restructuring charges and costs associated with a comprehensive operational efficiency program, totaling $266 million in the quarter. Despite the net loss, total revenue saw a modest increase of 1% to $1,175 million, driven by operational growth of 11% excluding foreign exchange impacts. Growth was observed in both U.S. and International segments, with companion animal sales particularly strong due to the Abbott Animal Health acquisition and the performance of key products like Apoquel. For the first six months of 2015, Zoetis reported a net income of $128 million, down from $291 million in the prior year, also impacted by restructuring charges. Revenue for the six-month period increased by 1% to $2,277 million, with operational revenue growth of 8%. The company's balance sheet shows a decrease in cash and cash equivalents to $544 million from $882 million, while inventories increased. The company's financial guidance for the full year 2015 anticipates adjusted diluted EPS between $1.63 and $1.68, indicating management's focus on core operational performance despite the significant one-time charges impacting GAAP net income.
Financial Highlights
53 data points| Revenue | $1.18B |
| Cost of Revenue | $427.00M |
| Gross Profit | $748.00M |
| SG&A Expenses | $379.00M |
| Operating Expenses | $936.00M |
| Interest Expense | $29.00M |
| Net Income | -$36.00M |
| EPS (Basic) | $-0.07 |
| EPS (Diluted) | $-0.07 |
| Shares Outstanding (Basic) | 500.17M |
| Shares Outstanding (Diluted) | 500.20M |
Key Highlights
- 1Reported a net loss of $37 million for Q2 2015, compared to a net income of $136 million in Q2 2014, primarily due to significant restructuring charges.
- 2Total revenue increased by 1% to $1,175 million in Q2 2015, with operational revenue growth (excluding foreign exchange) of 11%, driven by both U.S. and international markets.
- 3Companion animal sales saw strong operational growth of 15% in Q2 2015, boosted by the acquisition of Abbott Animal Health assets and strong performance of products like Apoquel.
- 4Livestock sales grew operationally by 8% in Q2 2015, across key species, supported by new product launches and recovery in the swine population post-PEDv outbreaks.
- 5Significant restructuring charges and costs associated with an operational efficiency program totaled $266 million in Q2 2015, impacting reported profitability.
- 6The company's cash position decreased to $544 million as of June 28, 2015, from $882 million as of December 31, 2014, with net cash used in financing activities increasing substantially due to share repurchases and dividend payments.
- 7Full-year 2015 guidance for adjusted diluted EPS was provided between $1.63 and $1.68, indicating expected underlying operational strength.